EQS-News

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO) - Seite 3

 
Chief Scientific Officer, Abivax EC24-1272
Poster Presentation-025 Poster Exhibition Hall A Feb. 23, 2024
Session time: 12:40–1:40 p.m. Efficacy and safety of de-escalation from 50 mg to 25 mg of oral, once-daily, obefazimod for the third and fifth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): An interim analysis Guided Poster Session Prof. Parambir S. Dulai, M.D.
 
Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University, Evanston, Illinois.  EC24-1277
Poster Presentaition-985 Poster Exhibition Hall A Feb. 23, 2024
Session time: 12:40-1:40 p.m.

About Obefazimod

Obefazimod, Abivax’s lead investigational drug candidate, is an oral small molecule that was demonstrated to enhance the expression of a single microRNA, miR-124. Phase 2 clinical trials in patients with UC have generated positive topline data, resulting in the initiation of a pivotal global Phase 3 clinical trial program (ABTECT Program), with first patients enrolled in the United States in October 2022. Initiation of a Phase 2b clinical trial in Crohn’s disease is expected in Q3 2024, and exploration of potential combination therapy opportunities in UC is ongoing.

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX.